Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID_ENZA Trial: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

NCT04456049 is registered in ClinicalTrials.gov with Ricardo Pereira Mestre as lead sponsor.

NCT NCT04456049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04456049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID_ENZA Trial: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
Lead sponsor
Ricardo Pereira Mestre
Phase
Phase 2
Overall status
Terminated
Start date
August 24, 2020
Completion date
June 9, 2021
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection